Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Privia Health Group Inc (NASDAQ: PRVA) closed at $23.94 up 0.08% from its previous closing price of $23.92. In other words, the price has increased by $0.08 from its previous closing price. On the day, 0.67 million shares were traded. PRVA stock price reached its highest trading level at $24.175 during the session, while it also had its lowest trading level at $23.7.
Ratios:
For a deeper understanding of Privia Health Group Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.67 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 26.87. For the most recent quarter (mrq), Quick Ratio is recorded 1.67 and its Current Ratio is at 1.67. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, BMO Capital Markets on November 13, 2025, initiated with a Outperform rating and assigned the stock a target price of $30.
On January 10, 2025, Needham started tracking the stock assigning a Buy rating and target price of $25.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 12 ’25 when Morris Matthew Shawn sold 13,647 shares for $25.01 per share. The transaction valued at 341,311 led to the insider holds 68,188 shares of the business.
Mountcastle David sold 23,887 shares of PRVA for $597,892 on Dec 12 ’25. The EVP & Chief Financial Officer now owns 172,909 shares after completing the transaction at $25.03 per share. On Dec 12 ’25, another insider, Matthew Shawn Morris, who serves as the Director of the company, bought 833,340 shares for $24.91 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRVA now has a Market Capitalization of 2944656640 and an Enterprise Value of 2563176704. As of this moment, Privia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 168.59, and their Forward P/E ratio for the next fiscal year is 76.16. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.28. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.44 while its Price-to-Book (P/B) ratio in mrq is 4.15. Its current Enterprise Value per Revenue stands at 1.255 whereas that against EBITDA is 68.742.
Stock Price History:
The Beta on a monthly basis for PRVA is 0.83, which has changed by 0.19182861 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, PRVA has reached a high of $26.51, while it has fallen to a 52-week low of $18.77. The 50-Day Moving Average of the stock is -1.97%, while the 200-Day Moving Average is calculated to be 3.98%.
Shares Statistics:
For the past three months, PRVA has traded an average of 837.09K shares per day and 673250 over the past ten days. A total of 122.87M shares are outstanding, with a floating share count of 109.25M. Insiders hold about 11.18% of the company’s shares, while institutions hold 93.83% stake in the company. Shares short for PRVA as of 1764288000 were 3103782 with a Short Ratio of 3.71, compared to 1761868800 on 3395452. Therefore, it implies a Short% of Shares Outstanding of 3103782 and a Short% of Float of 4.54.
Earnings Estimates
A detailed examination of Privia Health Group Inc (PRVA) is currently in progress, with 11.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.21, with high estimates of $0.28 and low estimates of $0.15.
Analysts are recommending an EPS of between $0.97 and $0.88 for the fiscal current year, implying an average EPS of $0.94. EPS for the following year is $1.05, with 11.0 analysts recommending between $1.2 and $0.77.
Revenue Estimates
A total of 15 analysts believe the company’s revenue will be $516.17M this quarter.It ranges from a high estimate of $552.1M to a low estimate of $493M. As of. The current estimate, Privia Health Group Inc’s year-ago sales were $460.9MFor the next quarter, 15 analysts are estimating revenue of $543.79M. There is a high estimate of $572.4M for the next quarter, whereas the lowest estimate is $516M.
A total of 15 analysts have provided revenue estimates for PRVA’s current fiscal year. The highest revenue estimate was $2.13B, while the lowest revenue estimate was $2.07B, resulting in an average revenue estimate of $2.1B. In the same quarter a year ago, actual revenue was $1.74BBased on 15 analysts’ estimates, the company’s revenue will be $2.31B in the next fiscal year. The high estimate is $2.38B and the low estimate is $2.22B.
